Thus, our findings suggested that similar to IFN-mediated upregulation of PD-L1 expression68, IFN-induced Gal-9 expression and secretion in tumors may be another mechanism of adaptive immune resistance that can be targeted for cancer immunotherapy. The gene discussed is LGALS9; the disease is cancer.